JPMorgan Chase & Co. Analysts Give Novartis (NOVN) a CHF 84 Price Target

JPMorgan Chase & Co. set a CHF 84 price objective on Novartis (VTX:NOVN) in a research note released on Wednesday. The firm currently has a neutral rating on the stock.

A number of other equities research analysts have also recently weighed in on NOVN. set a CHF 90 price target on Novartis and gave the company a buy rating in a research note on Tuesday, September 19th. Baader Bank set a CHF 90 price target on Novartis and gave the company a buy rating in a research note on Monday, October 30th. Barclays set a CHF 75 price target on Novartis and gave the company a sell rating in a research note on Wednesday, October 25th. Societe Generale set a CHF 95 price target on Novartis and gave the company a buy rating in a research note on Wednesday, October 25th. Finally, S&P Global set a CHF 87 price target on Novartis and gave the company a neutral rating in a research note on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of CHF 86.97.

Shares of Novartis (VTX NOVN) opened at CHF 83.88 on Wednesday. Novartis has a 12 month low of CHF 69.50 and a 12 month high of CHF 85.40. The firm has a market capitalization of $218,960.00 and a price-to-earnings ratio of 30.61.

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Analysts Give Novartis (NOVN) a CHF 84 Price Target” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/13/jpmorgan-chase-co-analysts-give-novartis-novn-a-chf-84-price-target-2.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply